AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03541447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
Study NCT03541447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: A single dose of two 20 mg i.m. injections.
Study NCT03541447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of two 20 mg i.m. injections.
Study NCT03895450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Protocol
Description: Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
Study NCT03895450 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise Protocol
Description: Participants randomized to AEP will be asked to exercise 30 minutes per day or until symptom exacerbation, 5 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
Study NCT03895450 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Protocol
Description: Participants will follow a stretching protocol for 30 minutes a day, 5 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
Study NCT02385110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks.
Study NCT02385110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide.
Study NCT02385110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks.
Study NCT02385110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
Study NCT02385110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
Study NCT02385110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
Study NCT02051335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast tablets
Study NCT02051335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast placebo
Description: Roflumilast placebo-matching tablets
Study NCT02051335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil overencapsulated tablets
Study NCT02051335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Donepezil placebo-matching overencapsulated tablets
Study NCT02051335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection
Study NCT00678964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg, p.o., once daily
Study NCT00678964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine and Carboplatin
Description: Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
Study NCT04238338 — intervention group
Intervention type: OTHER
Intervention: monocyte / lymphocyte ratio
Description: The lymphocyte / monocyte ratio should be tested every 3-6months after the start of the study, and the final value is the average
Study NCT00198523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone and Tobramycin
Study NCT00198523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT03739801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Given IV
Study NCT02757820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i- gel
Description: Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
Study NCT02757820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q
Description: Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
Study NCT03780647 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
Study NCT02706847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet; Oral
Study NCT02706847 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablet; Oral
Study NCT02706847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study NCT00675584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
Study NCT00675584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
Study NCT00675584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Budesonide
Description: Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
Study NCT00675584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Budesonide
Description: Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
Study NCT01174264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03739801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01174264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT02793310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMEK
Description: The intervention group will receive cornea transplantation by DMEK
Study NCT02793310 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSAEK
Description: The usual care / control group will receive cornea transplantation by DSAEK
Study NCT00884897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin given as 20 IU BID
Study NCT00884897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given as 20 IU BID
Study NCT01915797 — intervention group
Intervention type: OTHER
Intervention: blood and tumor samples
Description: all tumor pathology associated with anomaly of development
Study NCT04237285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation aromatherapy
Description: Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
Study NCT04237285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy
Description: Besides routine care, the Control Group was treated with jojoba oil (Simmondsia Chinensis- produced by Arifoğlu, obtained from jojoba fruits by cold squeezing method) inhalation aromatherapy 15 minutes before Hydrotherapy. Jojoba oil was used as a placebo because it had no specific odor. Besides routine care Intervention-15 Group received lavender oil (Lavandula angustifolia Miller Oleum-produced by Arifoğlu, obtained from lavender flowers by water vapor distillation method) inhalation aromatherapy 15 minutes before Hydrotherapy and besides routine care Intervention-60 Group received lavender oil inhalation aromatherapy 60 minutes before Hydrotherapy.
Study NCT00785954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAI-9803
Description: STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
Study NCT00785954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KAI-9803
Description: STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
Study NCT02102412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: screening colonoscopy
Description: performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
Study NCT00820261 — intervention group
Intervention type: OTHER
Intervention: oral rehydration therapy for diarrhea cases
Description: Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
Study NCT01508338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
Study NCT01508338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
Study NCT01508338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak ATP and HMB
Description: One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
Study NCT01508338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ATP
Description: One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
Study NCT04325633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: Naproxen
Description: Description : Administration of naproxen 250 mg twice and lansoprazole 30 mg daily for prevention of gastropathy induced by stress or a nonsteroidal anti-inflammatory drug (NSAID) in addition to standard of care (SOC)
Study NCT04325633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2: Standard of care
Description: Standard of care
Study NCT04325633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2: Standard of care
Description: Standard of care
Study NCT03330613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PAEDS
Description: pediatric emergency delirium scale
Study NCT03330613 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PAEDS
Description: pediatric emergency delirium scale
Study NCT03330613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TIVA
Description: Total intravenous anesthesia with propofol
Study NCT03330613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TIVA
Description: Total intravenous anesthesia with propofol
Study NCT03330613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inhalational anesthesia
Description: Inhalational (volatile) anesthesia with sevoflurane
Study NCT03330613 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational anesthesia
Description: Inhalational (volatile) anesthesia with sevoflurane
Study NCT01602510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
Study NCT01602510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02920840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent theta-burst stimulation
Description: see associated arm/group description
Study NCT02920840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative-peak-triggered-TMS
Description: see associated arm/group description
Study NCT02920840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop replay TMS
Description: see associated arm/group description
Study NCT00980590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Scope
Description: Tracheal intubation by Airway Scope
Study NCT00980590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh Laryngoscope
Description: Tracheal intubation by Macintosh Laryngoscope
Study NCT01844713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workbook
Description: Subjects will read a workbook about sun protection
Study NCT00547534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 on days 1, 4, 8, 11
Study NCT00547534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 90 mg/m\^2 days 1 and 4
Study NCT00547534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 day 1
Study NCT01151215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Tablet, oral, bd
Study NCT01151215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Tablet, oral, od
Study NCT01151215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anastrozole
Description: Tablet, oral, od
Study NCT01151215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral
Study NCT03463551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL-101
Description: ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
Study NCT03463551 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Placebo
Study NCT03850275 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: Subjects received all 3 interventions Placebo \~3mg caffeine Caffeinated placebo \~100mg caffeine E+shots- The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
Study NCT03739801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03739801 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study NCT00940576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mare´s milk
Description: oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
Study NCT00940576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mare´s milk
Description: oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
Study NCT00940576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo drink
Description: oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
Study NCT00940576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
Study NCT03745248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
Study NCT03745248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Standard of care
Study NCT01114295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule Endoscopy
Description: Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
Study NCT01114295 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Enterography
Description: CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
Study NCT04086381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: 5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
Study NCT04086381 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo cellulose
Description: oral ingestion of placebo containing 20 gram cellulose daily
Study NCT03724019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
Study NCT00758329 — intervention group
Intervention type: DEVICE
Intervention: ReCap Total Hip Resurfacing
Description: ReCap Total Hip Resurfacing
Study NCT03090503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Initial dose: 10 mg.
Study NCT03090503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose: 2 mg.